Navigation Links
New screening approach uncovers potential alternative drug therapies for neuroblastoma

Nearly two-thirds of patients with high-risk neuroblastoma a common tumor that forms in the nerve cells of childrencannot be cured using tumor-killing cancer drugs. A study published by Cell Press in the May 23 issue of Chemistry & Biology reveals a new genomic approach to screen for compounds that could inhibit tumor growth by causing cancer cells to differentiate, or convert from immature cells to more specialized cell types. Using this screening method, the researchers identified a compound that causes neuroblastoma cells to differentiate, uncovering a promising new treatment strategy for this highly malignant pediatric cancer.

"New treatment approaches are very much needed for children with high-risk childhood cancers; that is, those that are metastatic at diagnosis and likely to recur," says senior study author Kimberly Stegmaier of the Dana-Farber/Children's Hospital Cancer Center and the Broad Institute of the Massachusetts Institute of Technology and Harvard University. "By focusing on an alternative strategy to treating neuroblastoma tumors, we identified a compound class that in early testing in neuroblastoma cells in the laboratory shows promise for treating children with this disease."

Beyond the standard approach of using drugs that kill tumor cells, another promising strategy is to identify compounds that promote differentiation, which causes tumor cells to stop dividing and growing. But the benefits of differentiation therapy had not been fully explored.

To address this need, Stegmaier and her team developed a method to screen small molecules for their ability to trigger differentiation in neuroblastoma cells. First, they treated these cells with drugs known to induce differentiation and looked for accompanying changes in the activity levels of genes. They found that 59 genes showed changes related to differentiation. Using this genetic signature for differentiation, they then screened nearly 2,000 small molecules and identified one compound that strongly promoted differentiation in neuroblastoma cells, especially when combined with a drug already approved to treat this type of cancer.

The newly identified compound works by selectively inhibiting a subset of gene-regulating proteins called histone deacetylases (HDACs). "This work supports the need to develop selective HDAC inhibitors for clinical application and, more broadly, illuminates the power of integrating signature-based screening with new approaches to chemical synthesis to provide novel biological insights into human disease," Stegmaier says.


Contact: Mary Beth O'Leary
Cell Press

Related medicine news :

1. Genetic screening could reveal hidden high risk for coronary heart disease
2. Pulse Oximetry Screening for Newborns a Reality in North Carolina
3. Bay Area Hospital Selects BESLER Consulting’s BVerified (SM)- Screening and Verification Solution
4. Memorial Hospital Wellness Vehicle to Offer Health Screenings at Affordable Assisted Living Community in St. Louis Metro East
5. Water’s Edge Dermatology Offers Complimentary Skin Cancer Screenings in May for Skin Cancer Awareness Month
6. Outsourced Ion Channel Primary Screening Trends & 2015 Forecast in New Market Research Report at
7. PreCheck, Inc. Achieves Background Screening Credentialing Council Accreditation
8. PharmaSmart® and Kinney Drugs Partner up to Unveil Newest Advancement in Pharmacy-Based Biometric Screening and Mobile Interoperability
9. New Guidelines Suggest HIV Screening for All Adults
10. Personalizing prostate cancer screenings
11. Research finds targeted screening for hepatitis C is cost-effective
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... changing the way that they are handling security in light of the recent terrorist ... presence in an attempt to stop an attack from reaching U.S. soil. Especially around ...
(Date:11/27/2015)... ... 27, 2015 , ... "When I was traveling, I was ... N.J. "Many people catch diseases simply from sitting on such dirty toilet seats. ... from germs." , He developed the patent-pending QUDRATECS to eliminate the need to ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health ... both STEMI and Sepsis conditions present in similar ways and require time-critical intervention to ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Advanced Wound Care Market by Type (Dressings, Therapy ... User (In-Patient Facility, Out-Patient Facility), and Geography - Global ... --> --> The ... definition and forecast of the global advanced wound care ...
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
Breaking Medicine Technology: